Cost-Effectiveness of Erlotinib versus Docetaxel for Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer in the United Kingdom
Lewis, G., Peake, M., Aultman, R., Gyldmark, M., Morlotti, L., Creeden, J., de la Orden, M.Volume:
38
Language:
english
Journal:
Journal of International Medical Research
DOI:
10.1177/147323001003800102
Date:
February, 2010
File:
PDF, 314 KB
english, 2010